ACPA prevents lung fibroblast-to-CAF transformation by reprogramming the tumor microenvironment through NSCLC-derived exosomes
Özge Boyacıoğlu, Berfin Deniz Kalali, Tuba Reçber, Dilek Gelen-Gungor, Emirhan Nemutlu, İpek Eroğlu, Nedret Kılıç, Petek Korkusuz · 2025
Read ACPA prevents lung fibroblast-to-CAF transformation by reprogramming the tumor microenvironment through NSCLC-derived exosomes by Özge Boyacıoğlu, Berfin Deniz Kalali, Tuba Reçber, Dilek Gelen-Gungor, Emirhan Nemutlu, İpek Eroğlu, Nedret Kılıç, Petek Korkusuz (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12753834.txt.
Description
Özge Boyacıoğlu and co-authors test a compound that may block a step in lung cancer spread, in a 2025 study. Most lung cancers are the non-small cell type. Current drugs often cause wide side effects or stop working over time. Support cells called fibroblasts can turn into cancer-linked helpers that aid the tumor.
The compound, ACPA, acts on a cell receptor and had already shown anti-tumor effects. Treated cancer cells released tiny parcels called exosomes with changed contents. Those parcels lowered the survival of fibroblasts and cut markers of their shift into cancer helpers. Their inner chemistry changed across several pathways. The work points to treating the tumor's surroundings, not just the tumor.
Catalog record
| CREATOR | Özge Boyacıoğlu, Berfin Deniz Kalali, Tuba Reçber, Dilek Gelen-Gungor, Emirhan Nemutlu, İpek Eroğlu, Nedret Kılıç, Petek Korkusuz |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |